Epistem is applying its expertise in the behaviour of epithelial stem cells along with its high-resolution gene expression profiling technology to develop robust, non-invasive biomarkers that measures drug-induced changes in gene expression (mRNA) from individual hairs plucked from cancer patients undergoing treatment. 

Epistem believes its biomarker technology has the potential to provide valuable insights for decision-making in drug development in oncology:

• Drug exposure – measure the level of drug and time required to effect targeted signaling pathways
• Dose and schedule – measure duration of drug effects over dose range and time
• Toxicity  – provide early indication of toxicity